ERIN BROSAMER: Open Payments
NPI 1710534359 · ORANGE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,666 in 248 payments from 21 companies in 2025. Trend: 2023 $4,422 · 2024 $5,628 · 2025 $5,666
Food & beverage: $5,546Education: $120
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $716 |
| Janssen Pharmaceuticals, Inc | 19 | $674 |
| Otsuka America Pharmaceutical, Inc. | 25 | $564 |
| Teva Pharmaceuticals USA, Inc. | 22 | $539 |
| Vanda Pharmaceuticals Inc. | 21 | $467 |
| ABBVIE INC. | 19 | $449 |
| Alkermes, Inc. | 20 | $447 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $446 |
| Lundbeck LLC | 15 | $301 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $209 |
Products named: INGREZZA, REXULTI, SPRAVATO, FANAPT, VRAYLAR, ARISTADA, CAPLYTA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
